Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Dr. Rothenberg Impact on THTX and CADL
View:
Post by SPCEO1 on Oct 27, 2021 5:39pm

Dr. Rothenberg Impact on THTX and CADL

CADL announced the appointment of Dr. Rothenberg in a standalone press release on 10/19. There has been no other news reported on Bloomberg since then on CADL. CADL's stock price is 19% higher than before the Rothenberg announcement.

THTX announced the appoinitment of Dr. Rothenberg on 10/13 and it was buried in the Q3 financial report press release. THTX stock price has beenflat since this announcement (closing at $3.49 today versus $3.50 the day before Rothenberg's appointment was announced).

Does anyone sense a theme here???? Over and over and over again, other similiar stocks do far, far better than THTX even when the news is identical, as in this case. 

Something is not right and I hope it gets fixed before THTX has any really good news to announce on the cancer front. At this point, I amm beginning to wonder of THTX announced TH-1902 had cured cancer if there would be much of a reaction. THTX's stock price seems impervious to the news coming from the company and the overall market movements. Apparently, it is a $3.50 stock and it is seems at this point it will always be a $3.50 stock! 

Sorry for the frustration I expressed above but it is well past ridiculous at this point.
Comment by qwerty22 on Oct 27, 2021 5:47pm
They had 2 presentations today at a science conference and most of that 19% seems to have happened in the past 2 days in anticipation of this.  
Comment by Momo25 on Oct 28, 2021 8:29am
This board can never do the right things to attract investors. A failure over many failures!
Comment by SPCEO1 on Oct 28, 2021 9:49am
Apparently, CADL has some work to do on the IR front too as they did not put out a press release about those presentations. Perhpas they were not that significant and did not justify a press release but the price reaction seems to indicate they were.
Comment by SPCEO1 on Oct 28, 2021 10:05am
Just pulled CADL up on Bloomberg and ee that they did put out press releases this morning. 
Comment by Wino115 on Oct 27, 2021 5:51pm
It's frustrating, and I know it's not just about this advisor appointment as something like that shouldn't add much to SP - but point well taken.  I think it's that issue we've identified that they have unfortunately built a high hurdle of skepticism that has to be overcome because no one really follows them or looks at it as having a solid investment thesis to back a buy ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities